A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

1. Baselga, J.
2. Morales, S.M.
3. Awada, A.
4. Blum, J.L.
5. Tan, A.R.
6. Ewertz, M.
7. Cortes, J.
8. Moy, B.
9. Ruddy, K.J.
10. Haddad, T.
11. Ciruelos, E.M.
12. Vuylsteke, P.
13. Ebbinghaus, S.
14. Im, E.
15. Eaton, L.
16. Pathiraja, K.
17. Gause, C.
18. Mauro, D.
19. Jones, M.B.
20. Rugo, H.S.